1
|
Sharaf MS. Scabies vaccines: where we stand and challenges ahead. Parasitol Res 2024; 123:285. [PMID: 39046602 PMCID: PMC11269436 DOI: 10.1007/s00436-024-08298-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Accepted: 07/10/2024] [Indexed: 07/25/2024]
Abstract
Scabies is an itchy skin disease caused by the burrowing mite, Sarcoptes scabiei. During their lifespan, female mites invade the stratum corneum and create tunnels in which they reside, move, feed, deposit fecal pellets, and lay eggs. Globally, more than 200 million people are estimated to be affected by scabies annually. Currently, using scabicidal agents is the only approved method for treating scabies. However, resistance to commonly used agents such as permethrin and ivermectin has been observed in scabies mites. Therefore, the development of vaccines for scabies, either as a preventative measure or for treatment, is crucial to control such neglected diseases. Since the host could evolve a protective immune response that could prevent re-infestation by scabies mites, vaccine development is theoretically possible. This review aims to provide a comprehensive overview of the ongoing challenges regarding the currently available control measures for scabies. It also explores the promising path of scabies vaccine development, highlighting the current state of research and challenges that need to be addressed to develop new and innovative measures for both treating and preventing scabies infections.
Collapse
Affiliation(s)
- Mahmoud S Sharaf
- Parasitology Department, Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
| |
Collapse
|
2
|
Takano K, Carver S, Vermaak Y, Fischer K, Harvey RJ, Mounsey KE. Assessment of the in vitro acaricidal activity of Bravecto ® (fluralaner) and a proposed orange oil-based formulation vehicle for the treatment of Sarcoptes scabiei. Parasit Vectors 2024; 17:194. [PMID: 38664829 PMCID: PMC11046784 DOI: 10.1186/s13071-024-06275-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Accepted: 04/09/2024] [Indexed: 04/28/2024] Open
Abstract
BACKGROUND Sarcoptic mange is a serious animal welfare concern in bare-nosed wombats (Vombatus ursinus). Fluralaner (Bravecto®) is a novel acaricide that has recently been utilised for treating mange in wombats. The topical 'spot-on' formulation of fluralaner can limit treatment delivery options in situ, but dilution to a volume for 'pour-on' delivery is one practicable solution. This study investigated the in vitro acaricidal activity of Bravecto, a proposed essential oil-based diluent (Orange Power®), and two of its active constituents, limonene and citral, against Sarcoptes scabiei. METHODS Sarcoptes scabiei were sourced from experimentally infested pigs. In vitro assays were performed to determine the lethal concentration (LC50) and survival time of the mites when exposed to varying concentrations of the test solutions. RESULTS All compounds were highly effective at killing mites in vitro. The LC50 values of Bravecto, Orange Power, limonene and citral at 1 h were 14.61 mg/ml, 4.50%, 26.53% and 0.76%, respectively. The median survival times of mites exposed to undiluted Bravecto, Orange Power and their combination were 15, 5 and 10 min, respectively. A pilot survival assay of mites collected from a mange-affected wombat showed survival times of < 10 min when exposed to Bravecto and Orange Power and 20 min when exposed to moxidectin. CONCLUSIONS These results confirm the acaricidal properties of Bravecto, demonstrate acaricidal properties of Orange Power and support the potential suitability of Orange Power and its active constituents as a diluent for Bravecto. As well as killing mites via direct exposure, Orange Power could potentially enhance the topical delivery of Bravecto to wombats by increasing drug penetration in hyperkeratotic crusts. Further research evaluating the physiochemical properties and modes of action of Orange Power and its constituents as a formulation vehicle would be of value.
Collapse
Affiliation(s)
- Kotaro Takano
- School of Health, University of the Sunshine Coast, Maroochydore, QLD, Australia
- Sunshine Coast Health Institute, Birtinya, QLD, Australia
| | - Scott Carver
- Odum School of Ecology, University of Georgia, Georgia, USA
- Center for the Ecology of Infectious Diseases, University of Georgia, Georgia, 30602, USA
| | - Yolandi Vermaak
- Wombat Support and Rescue NSW/ACT Inc., Australian Capital Territory, Canberra, Australia
| | - Katja Fischer
- Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Robert J Harvey
- School of Health, University of the Sunshine Coast, Maroochydore, QLD, Australia
- Sunshine Coast Health Institute, Birtinya, QLD, Australia
| | - Kate E Mounsey
- School of Health, University of the Sunshine Coast, Maroochydore, QLD, Australia.
- Sunshine Coast Health Institute, Birtinya, QLD, Australia.
| |
Collapse
|
3
|
Blaizot R, Armanville F, Michaud C, Boceno C, Dupart O, Pansart C, Niemetzky F, Couppie P, Nacher M, Adenis A, Chosidow O, Duvignaud A. Scabies in French Guiana: Quantitative and qualitative factors associated with therapeutic failure. J Eur Acad Dermatol Venereol 2024; 38:602-612. [PMID: 38041562 DOI: 10.1111/jdv.19688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 11/08/2023] [Indexed: 12/03/2023]
Abstract
BACKGROUND Strategies for the control of scabies should be adapted to local settings. Traditional communities in French Guiana have non-Western conceptions of disease and health. OBJECTIVES The objectives for this study were to explore knowledge, attitudes and practices to identify potential factors associated with the failure of scabies treatment in these communities. METHODS Patients with a clinical diagnosis of scabies, seen at either the Cayenne Hospital or one of 13 health centres between 01 April 2021 and 31 August 2021, were included as participants, and were seen again after 6 weeks to check for persistence of lesions. Factors associated with treatment failure were looked for both at inclusion and at 6 weeks. Semi-structured interviews were conducted with a diversified subsample of participants. RESULTS In total, 164 participants were included in the quantitative component, and 21 were interviewed for the qualitative component. Declaring that the second treatment dose had been taken was associated with therapeutic success. Western treatments were not always affordable. Better adherence was observed with topical treatments than with oral ivermectin, whereas permethrin monotherapy was associated with failure. Scabies-associated stigma was high among Amerindians and Haitians but absent in Ndjuka Maroons. Participants reported environmental disinfection as being very complex. CONCLUSIONS The treatment of scabies in traditional Guianan communities may vary depending on local perceptions of galenic formulations, disease-associated stigma and differences in access to health care. These factors should be taken into account when devising strategies for the control of scabies aimed at traditional communities living in remote areas, and migrant populations.
Collapse
Affiliation(s)
- R Blaizot
- Centre Hospitalier de Cayenne, Service de Dermatologie, Cayenne, French Guiana
- Centre Hospitalier de Cayenne Inserm CIC 1424, Centre d'Investigations Cliniques, Cayenne, French Guiana
- UMR 1019 Tropical Biomes and Immunophysiopathology (TBIP), Université de Guyane, Cayenne, French Guiana
- Groupe Infectiologie Dermatologique- Infections Sexuellement Transmissibles, Société Française de Dermatologie, Paris, France
- Centre Hospitalier de Cayenne, Centres Délocalisés de Prévention et de Soins, Cayenne, French Guiana
| | - F Armanville
- Centre Hospitalier de Cayenne, Centres Délocalisés de Prévention et de Soins, Cayenne, French Guiana
| | - C Michaud
- Centre Hospitalier de Cayenne, Centres Délocalisés de Prévention et de Soins, Cayenne, French Guiana
| | - C Boceno
- Centre Hospitalier de Cayenne, Permanence d'Accès aux Soins de Santé, Cayenne, French Guiana
| | - O Dupart
- Centre Hospitalier de Cayenne, Permanence d'Accès aux Soins de Santé, Cayenne, French Guiana
| | - C Pansart
- Centre Hospitalier de Cayenne, Permanence d'Accès aux Soins de Santé, Cayenne, French Guiana
| | - F Niemetzky
- Centre Hospitalier de Cayenne, Centres Délocalisés de Prévention et de Soins, Cayenne, French Guiana
| | - P Couppie
- Centre Hospitalier de Cayenne, Service de Dermatologie, Cayenne, French Guiana
- UMR 1019 Tropical Biomes and Immunophysiopathology (TBIP), Université de Guyane, Cayenne, French Guiana
| | - M Nacher
- Centre Hospitalier de Cayenne Inserm CIC 1424, Centre d'Investigations Cliniques, Cayenne, French Guiana
| | - A Adenis
- Centre Hospitalier de Cayenne Inserm CIC 1424, Centre d'Investigations Cliniques, Cayenne, French Guiana
| | - O Chosidow
- Groupe Infectiologie Dermatologique- Infections Sexuellement Transmissibles, Société Française de Dermatologie, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire La Pitié-Salpêtrière, Paris, France
| | - A Duvignaud
- Department of Infectious Diseases and Tropical Medicine, CHU Bordeaux, Bordeaux, France
- Bordeaux Population Health Centre, University of Bordeaux, INSERM UMR 1219, IRD EMR 271, Bordeaux, France
| |
Collapse
|
4
|
Mbuagbaw L, Sadeghirad B, Morgan RL, Mertz D, Motaghi S, Ghadimi M, Babatunde I, Zani B, Pasumarthi T, Derby M, Kothapudi VN, Palmer NR, Aebischer A, Harder T, Reichert F. Failure of scabies treatment: a systematic review and meta-analysis. Br J Dermatol 2024; 190:163-173. [PMID: 37625798 DOI: 10.1093/bjd/ljad308] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 08/18/2023] [Accepted: 08/20/2023] [Indexed: 08/27/2023]
Abstract
BACKGROUND Treatment failure is considered to be an important factor in relation to the increase in scabies incidence over the last decade. However, the regional and temporal differences, in addition to the predictors of therapy failure, are unclear. OBJECTIVES We aimed to conduct a systematic review of the prevalence of treatment failure in patients with scabies and investigation of associated factors. METHODS We searched MEDLINE, EMBASE, CINAHL, Web of Science, Scopus, Global Health and the Cochrane Central Register of Controlled Trials from inception to August 2021 for randomized and quasi-randomized trials, in addition to observational studies that enrolled children or adults diagnosed with confirmed or clinical scabies treated with permethrin, ivermectin, crotamiton, benzyl benzoate, malathion, sulfur or lindane, and measured treatment failure or factors associated with treatment failure. We performed a random effects meta-analysis for all outcomes reported by at least two studies. RESULTS A total of 147 studies were eligible for inclusion in the systematic review. The overall prevalence of treatment failure was 15.2% [95% confidence interval (CI) 12.9-17.6; I2 = 95.3%, moderate-certainty evidence] with regional differences between World Health Organization regions (P = 0.003) being highest in the Western Pacific region (26.9%, 95% CI 14.5-41.2). Oral ivermectin (11.8%, 95% CI 8.4-15.4), topical ivermectin (9.3%, 95% CI 5.1-14.3) and permethrin (10.8%, 95% CI 7.5-14.5) had relatively lower failure prevalence compared with the overall prevalence. Failure prevalence was lower in patients treated with two doses of oral ivermectin (7.1%, 95% CI 3.1-12.3) compared with those treated with one dose (15.2%, 95% CI 10.8-20.2; P = 0.021). Overall and permethrin treatment failure prevalence in the included studies (1983-2021) increased by 0.27% and 0.58% per year, respectively. Only three studies conducted a multivariable risk factor analysis; no studies assessed resistance. CONCLUSIONS A second dose of ivermectin showed lower failure prevalence than single-dose ivermectin, which should be considered in all guidelines. The increase in treatment failure over time hints at decreasing mite susceptibility for several drugs, but reasons for failure are rarely assessed. Ideally, scabicide susceptibility testing should be implemented in future studies.
Collapse
Affiliation(s)
- Lawrence Mbuagbaw
- Biostatistics Unit/The Research Institute, St Joseph's Healthcare, Hamilton, ON, Canada
- Department of Health Research Methods, Evidence, and Impact
- Department of Anesthesia
| | - Behnam Sadeghirad
- Department of Health Research Methods, Evidence, and Impact
- Department of Anesthesia
- Michael G. DeGroote National Pain Centre
| | - Rebecca L Morgan
- Department of Health Research Methods, Evidence, and Impact
- Evidence Foundation, Cleveland Heights, OH, USA
- School of Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - Dominik Mertz
- Department of Health Research Methods, Evidence, and Impact
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | | | - Maryam Ghadimi
- Department of Health Research Methods, Evidence, and Impact
| | | | - Babalwa Zani
- Knowledge Translation Unit, University of Cape Town Lung Institute, Rondebosch, South Africa
| | | | | | | | | | | | - Thomas Harder
- Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
| | - Felix Reichert
- Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
| |
Collapse
|
5
|
Sharaf MS, Othman AA, Abd El Ghaffar AE, Ali DM, Eid MM. Evaluation of the scabicidal effect of a single dose of fluralaner in a rabbit model of crusted scabies. Parasitol Res 2023; 122:2477-2490. [PMID: 37656230 PMCID: PMC10567865 DOI: 10.1007/s00436-023-07945-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Accepted: 08/11/2023] [Indexed: 09/02/2023]
Abstract
Recently, scabies was included in the WHO roadmap for neglected tropical diseases 2021-2030. Till now, ivermectin is the only available oral drug that is currently approved for treating crusted scabies in humans. Concerns regarding its efficacy and safety have prompted research efforts to find new alternatives. Our study aimed to evaluate the therapeutic effect of a single dose of fluralaner in cases of crusted scabies in comparison with that of repeated weekly high doses of ivermectin. For the in vitro study, twenty adult female mites were exposed to 50 μg/ml and 100 μg/ml ivermectin and fluralaner to evaluate their effects on mites' survival. For the in vivo study, thirty-five male crossbreed rabbits were divided into 4 groups: group I (non-infected, non-treated), group II (infected, non-treated), group III (infected and treated with ivermectin in a weekly oral dose of 0.4 mg/kg body weight/rabbit for 4 weeks, starting 8 weeks post-infection), and group IV (infected and treated with fluralaner given as a single oral dose of 25 mg/kg body weight/rabbit, starting 8 weeks post-infection). Clinical, parasitological, histopathological, and biochemical assessments were done. Clinical and parasitological assays were accomplished to all infected groups starting from day 0, then on days 2, 4, 6, 8, 10, 12, 14, 21, 28, 35, 42, 49 and 56 post-treatment, while histopathological and biochemical assessments were done at the end of the 8th week post-treatment (day 56). Our results showed that fluralaner exhibited a higher acaricidal effect on adult Sarcoptes scabiei var. cuniculi when compared with ivermectin applied in the same concentration (50 μg/ml or 100 μg/ml). Concerning the in vivo study, both clinical cure and parasitological cure were noted in both treated groups, evidenced by complete absence of all clinical signs of infestation and absence of mites in all skin scrapings. However, the ivermectin-treated group showed incomplete histopathological and biochemical resolution. Interestingly, both clinical cure and negative skin scrapings were noticed earlier in the fluralaner-treated group, with no apparent side effects. Also, no significant differences were noticed in the skin sections and serum biochemical parameters when compared with those of the negative control group. We concluded that fluralaner is a promising scabicidal agent that is recommended to be studied for possible human use, especially in control programs.
Collapse
Affiliation(s)
- Mahmoud S Sharaf
- Parasitology Department, Faculty of Medicine, Tanta University, Elgeish Street, Tanta, Egypt.
| | - Ahmad A Othman
- Parasitology Department, Faculty of Medicine, Tanta University, Elgeish Street, Tanta, Egypt
| | - Amira E Abd El Ghaffar
- Parasitology Department, Faculty of Medicine, Tanta University, Elgeish Street, Tanta, Egypt
| | - Dareen M Ali
- Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt
| | - Mohamed M Eid
- Parasitology Department, Faculty of Medicine, Tanta University, Elgeish Street, Tanta, Egypt
| |
Collapse
|
6
|
Liao F, Han C, Deng Q, Zhou Z, Bao T, Zhong M, Tao G, Li R, Han B, Qiao Y, Hu Y. Natural Products as Mite Control Agents in Animals: A Review. Molecules 2023; 28:6818. [PMID: 37836661 PMCID: PMC10574536 DOI: 10.3390/molecules28196818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 09/19/2023] [Accepted: 09/25/2023] [Indexed: 10/15/2023] Open
Abstract
Mites have been a persistent infectious disease affecting both humans and animals since ancient times. In veterinary clinics, the primary approach for treating and managing mite infestations has long been the use of chemical acaricides. However, the widespread use of these chemicals has resulted in significant problems, including drug resistance, drug residues, and environmental pollution, limiting their effectiveness. To address these challenges, researchers have shifted their focus towards natural products that have shown promise both in the laboratory and real-world settings against mite infestations. Natural products have a wide variety of chemical structures and biological activities, including acaricidal properties. This article offers a comprehensive review of the acaricidal capabilities and mechanisms of action of natural products like plant extracts, natural compounds, algae, and microbial metabolites against common animal mites.
Collapse
Affiliation(s)
- Fei Liao
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China;
| | - Changquan Han
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
| | - Qingsheng Deng
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
| | - Ziyao Zhou
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China;
| | - Taotao Bao
- Qiandongnan Center for Animal Disease Control and Prevention, Kaili 556000, China;
| | - Menghuai Zhong
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
| | - Guangyao Tao
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
| | - Renjun Li
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
| | - Bo Han
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
| | - Yanlong Qiao
- Department of Animal Husbandry and Fisheries, Guizhou Vocational College of Agriculture, Qingzhen 551400, China; (F.L.); (C.H.); (Q.D.); (M.Z.); (G.T.); (R.L.); (B.H.)
| | - Yanchun Hu
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China;
| |
Collapse
|
7
|
Feng S, Shi M, Yin Z, Di W, Guillot J, Fang F. Can Ivermectin kill Sarcoptes scabiei during the molting process? PLoS Negl Trop Dis 2023; 17:e0011337. [PMID: 37196006 DOI: 10.1371/journal.pntd.0011337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 05/30/2023] [Accepted: 04/26/2023] [Indexed: 05/19/2023] Open
Abstract
BACKGROUND Sarcoptes scabiei is a permanent obligate ectoparasite that lives and reproduces in the epidermis of humans and other mammals worldwide. There is a lack of information on the molting process of Sarcoptes scabiei. Ivermectin is widely used to treat Sarcoptes infection in humans and animals, while the survival of molting Sarcoptes mites in the presence of ivermectin is unknown. The aim of the present study is to investigate the molting process of Sarcoptes mites and assess the activity of ivermectin during the molting process of Sarcoptes mites. METHODOLOGY/PRINCIPAL FINDINGS molting Sarcoptes mites were incubated at 35°C and 80% relative humidity and observed hourly until complete molt. Of the 192 molting mites recorded, the longest molt periods for larvae and nymphs were 23 and 30 h, respectively. The activity of ivermectin on molting Sarcoptes mites was also assessed using two concentrations of the drug (0.1 and 0.05 mg/ml). The exposure time for molting mites was determined by 100% mortality of female mites exposed to the solution of ivermectin. While all female mites were killed after exposure to 0.1 mg/ml ivermectin for 2 h and and 0.05 mg/ml for 7 h, 32% and 36% of molting mites survived and successfully molted, respectively. CONCLUSIONS/SIGNIFICANCE The present study demonstrated that molting Sarcoptes mites are less susceptible to ivermectin than active mites. As a consequence, mites may survive after two doses of ivermectin given 7 days apart due not only to hatching eggs but also to the resistance of mites during their molting process. Our results provide insight into the optimal therapeutic regimens for scabies and highlight the need for further research on the molting process of Sarcoptes mites.
Collapse
Affiliation(s)
- Shenrui Feng
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Minmin Shi
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Zhijuan Yin
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Wenda Di
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Jacques Guillot
- Dermatology-Parasitology-Mycology Departement, ONIRIS, Nantes, France
| | - Fang Fang
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| |
Collapse
|
8
|
Li M, Feng S, Huang S, Guillot J, Fang F. In Vitro Efficacy of Terpenes from Essential Oils against Sarcoptes scabiei. Molecules 2023; 28:molecules28083361. [PMID: 37110595 PMCID: PMC10143962 DOI: 10.3390/molecules28083361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 04/04/2023] [Accepted: 04/06/2023] [Indexed: 04/29/2023] Open
Abstract
The mite Sarcoptes scabiei is responsible for the emerging or re-emerging skin disease called scabies in humans and sarcoptic mange in animals. Essential oils represent an appealing alternative strategy for the control of Sarcoptes infections, but the commercial development of essential oils may be hampered by their inconsistency in efficacy due to their varied chemical compositions. In order to address this issue, we assessed the efficacy of six components (carvacrol, eugenol, geraniol, citral, terpinen-4-ol, and linalool) against S. scabiei. At a concentration of 0.5%, carvacrol presented the best miticidal efficacy, with a median lethal time (LT50) value of 6.7 min, followed by eugenol (56.3 min), geraniol (1.8 h), citral (6.1 h), terpinen-4-ol (22.3 h), and linalool (39.9 h). The LC50 values at 30 min for carvacrol, eugenol, and geraniol were 0.24, 0.79, and 0.91%, respectively. In conclusion, carvacrol, eugenol, and geraniol represent potential complementary or alternative agents for S. scabiei infections in humans or animals. Our study provides a scientific basis for the development of scabicidal products based on essential oils.
Collapse
Affiliation(s)
- Meilin Li
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning 530004, China
- Department of Pathogenic Biology, Army Medical University (Third Military Medical University), Chongqing 400038, China
| | - Shenrui Feng
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning 530004, China
| | - Siyi Huang
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning 530004, China
| | - Jacques Guillot
- Dermatology-Parasitology-Mycology Departement, Oniris, 100 Route de Gachet, 44300 Nantes, France
| | - Fang Fang
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning 530004, China
- Guangxi Zhuang Autonomous Region Engineering Research Center of Veterinary Biologics, Nanning 530004, China
- Guangxi Key Laboratory of Animal Reproduction, Breeding and Disease Control, Nanning 530004, China
| |
Collapse
|
9
|
Takano K, de Hayr L, Carver S, Harvey RJ, Mounsey KE. Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife. Int J Parasitol Drugs Drug Resist 2023; 21:97-113. [PMID: 36906936 PMCID: PMC10023865 DOI: 10.1016/j.ijpddr.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 02/15/2023] [Accepted: 02/20/2023] [Indexed: 03/07/2023]
Abstract
Sarcoptes scabiei is the microscopic burrowing mite responsible for sarcoptic mange, which is reported in approximately 150 mammalian species. In Australia, sarcoptic mange affects a number of native and introduced wildlife species, is particularly severe in bare-nosed wombats (Vombatus ursinus) and an emerging issue in koala and quenda. There are a variety of acaricides available for the treatment of sarcoptic mange which are generally effective in eliminating mites from humans and animals in captivity. In wild populations, effective treatment is challenging, and concerns exist regarding safety, efficacy and the potential emergence of acaricide resistance. There are risks where acaricides are used intensively or inadequately, which could adversely affect treatment success rates as well as animal welfare. While reviews on epidemiology, treatment strategies, and pathogenesis of sarcoptic mange in wildlife are available, there is currently no review evaluating the use of specific acaricides in the context of their pharmacokinetic and pharmacodynamic properties, and subsequent likelihood of emerging drug resistance, particularly for Australian wildlife. This review critically evaluates acaricides that have been utilised to treat sarcoptic mange in wildlife, including dosage forms and routes, pharmacokinetics, mode of action and efficacy. We also highlight the reports of resistance of S. scabiei to acaricides, including clinical and in vitro observations.
Collapse
Affiliation(s)
- Kotaro Takano
- School of Health, University of the Sunshine Coast, Maroochydore, Queensland, Australia; Sunshine Coast Health Institute, Birtinya, QLD, Australia
| | - Lachlan de Hayr
- School of Health, University of the Sunshine Coast, Maroochydore, Queensland, Australia; Sunshine Coast Health Institute, Birtinya, QLD, Australia
| | - Scott Carver
- Department of Biological Sciences, University of Tasmania, Hobart, Tasmania, Australia
| | - Robert J Harvey
- School of Health, University of the Sunshine Coast, Maroochydore, Queensland, Australia; Sunshine Coast Health Institute, Birtinya, QLD, Australia
| | - Kate E Mounsey
- School of Health, University of the Sunshine Coast, Maroochydore, Queensland, Australia; Sunshine Coast Health Institute, Birtinya, QLD, Australia.
| |
Collapse
|
10
|
Taylor S, Walther D, Fernando DD, Swe-Kay P, Fischer K. Investigating the Antibacterial Properties of Prospective Scabicides. Biomedicines 2022; 10:biomedicines10123287. [PMID: 36552044 PMCID: PMC9776028 DOI: 10.3390/biomedicines10123287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 12/02/2022] [Accepted: 12/12/2022] [Indexed: 12/24/2022] Open
Abstract
Scabies is a dermatological disease found worldwide. Mainly in tropical regions, it is also the cause of significant morbidity and mortality due to its association with potentially severe secondary bacterial infections. Current treatment strategies for scabies do not consider the role of opportunistic bacteria, and here we investigate whether current and emerging scabicides can offer any anti-bacterial protection. Using the broth microdilution method, we examined antimicrobial potential of the current scabicide ivermectin and emerging scabies treatments: abametapir, mānuka oil, and its individual β-triketones. Our results demonstrate that the two novel scabicides abametapir and mānuka oil have antimicrobial properties against common scabies-associated bacteria, specifically Staphylococcus aureus, Streptococcus pyogenes, Streptococcus dysgalactiae subsp. equisimilis and Acinetobacter baumannii. The current scabicide ivermectin offers some antimicrobial activity and is capable of inhibiting the growth aforementioned bacteria. This research is important as it could help to inform future best treatment options of scabies, and scabies-related impetigo.
Collapse
|
11
|
Fernando DD, Fischer K. Spinosad topical suspension (0.9%): a new topical treatment for scabies. Expert Rev Anti Infect Ther 2022; 20:1149-1154. [PMID: 35799317 DOI: 10.1080/14787210.2022.2099376] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Scabies is a highly contagious skin disease caused by the parasitic mite Sarcoptes scabiei. There is no vaccine and for the past 30 years, the first line treatments have been topical permethrin and oral ivermectin. These drugs target mainly the parasite nervous system, killing only the motile stages. As they lack ovicidal activities, repeat treatments are required to achieve complete cure. Incompliance to repeat treatments causing prolonged drug usage, has contributed to emerging drug resistances. In addition, they are not appropriate for all patient categories, specifically for infants and young children or pregnant and breast feeding women. Consequently, new single dose scabicides are urgently needed. AREAS COVERED In 2021, spinosad, a drug previously used to treat head lice, was approved by the US FDA as a topical scabies treatment. Here the pharmacology, clinical efficacy and tolerability of this drug are discussed. EXPERT OPINION As the first single dose scabicide the formulated 0.9% topical Spinosad solution shows significant efficacy, little systemic absorption and no serious adverse reactions, making it a promising treatment for classical scabies in patients older than four years.
Collapse
Affiliation(s)
- Deepani D Fernando
- Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia
| | - Katja Fischer
- Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia
| |
Collapse
|
12
|
Fernando DD, Korhonen PK, Gasser RB, Fischer K. An RNA Interference Tool to Silence Genes in Sarcoptes scabiei Eggs. Int J Mol Sci 2022; 23:ijms23020873. [PMID: 35055058 PMCID: PMC8777771 DOI: 10.3390/ijms23020873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 01/05/2022] [Accepted: 01/11/2022] [Indexed: 12/10/2022] Open
Abstract
In a quest for new interventions against scabies-a highly significant skin disease of mammals, caused by a parasitic mite Sarcoptes scabiei-we are focusing on finding new intervention targets. RNA interference (RNAi) could be an efficient functional genomics approach to identify such targets. The RNAi pathway is present in S. scabiei and operational in the female adult mite, but other developmental stages have not been assessed. Identifying potential intervention targets in the egg stage is particularly important because current treatments do not kill this latter stage. Here, we established an RNAi tool to silence single-copy genes in S. scabiei eggs. Using sodium hypochlorite pre-treatment, we succeeded in rendering the eggshell permeable to dsRNA without affecting larval hatching. We optimised the treatment of eggs with gene-specific dsRNAs to three single-copy target genes (designated Ss-Cof, Ss-Ddp, and Ss-Nan) which significantly and repeatedly suppressed transcription by ~66.6%, 74.3%, and 84.1%, respectively. Although no phenotypic alterations were detected in dsRNA-treated eggs for Ss-Cof and Ss-Nan, the silencing of Ss-Ddp resulted in a 38% reduction of larval hatching. This RNAi method is expected to provide a useful tool for larger-scale functional genomic investigations for the identification of essential genes as potential drug targets.
Collapse
Affiliation(s)
- Deepani D. Fernando
- Infectious Diseases Program, Cell and Molecular Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia;
| | - Pasi K. Korhonen
- Department of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville, VIC 3052, Australia; (P.K.K.); (R.B.G.)
| | - Robin B. Gasser
- Department of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville, VIC 3052, Australia; (P.K.K.); (R.B.G.)
| | - Katja Fischer
- Infectious Diseases Program, Cell and Molecular Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia;
- Correspondence:
| |
Collapse
|
13
|
Li M, Liu S, Yin Z, Bernigaud C, Guillot J, Fang F. Activity of terpenes derived from essential oils against Sarcoptes scabiei eggs. Parasit Vectors 2021; 14:600. [PMID: 34886874 PMCID: PMC8656058 DOI: 10.1186/s13071-021-05094-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 11/09/2021] [Indexed: 11/30/2022] Open
Abstract
Background The limited ovicidal activity of currently available acaricides is a significant obstacle to efficacious scabies treatment. Several essential oils or their respective components have proved to be active against the eggs of arthropods, mainly lice and ticks. Information on the activity of these oils and/or components against the eggs of mites remains very limited. The aim of this study was to assess the activity of six terpenes (carvacrol, eugenol, geraniol, citral, terpinen-4-ol and linalool) commonly found in essential oils against the eggs of Sarcoptes scabiei. Methods Sarcoptes eggs were exposed to paraffin oil containing 1, 2.5, or 5% of each terpene tested. After a 12-h exposure period, the eggs were washed and placed in paraffin oil for hatching. Embryonic development following treatment was assessed every day to determine the stage of developmental arrest. Results The median effective concentration to obtain 50% egg mortality (EC50) was 0.5, 0.9, 2.0, 4.8, 5.1 and 9.8% for carvacrol, eugenol, geraniol, citral, terpinen-4-ol and linalool, respectively. The microscopic images of eggs after each treatment indicated that these six terpenes may act by penetrating through the aeropyles on the egg surface. Conclusions In conclusion, carvacrol, eugenol and geraniol possess significant ovicidal activities, which should be considered as promising ovicidal agents for the treatment of scabies. Graphical Abstract ![]()
Collapse
Affiliation(s)
- Meilin Li
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Shunlong Liu
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Zhijuan Yin
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Charlotte Bernigaud
- Dynamic, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est Créteil (UPEC), 7 Avenue du Général de Gaulle, 94700, Maisons-Alfort, France.,Dermatology Department, Faculté de Santé, Hôpital Henri Mondor-Université Paris-Est Créteil, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France
| | - Jacques Guillot
- Dynamic, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est Créteil (UPEC), 7 Avenue du Général de Gaulle, 94700, Maisons-Alfort, France.,Dermatology Parasitology Mycology Department, Ecole Nationale Vétérinaire , Agroalimentaire et de l'Alimentation (ONIRIS), Nantes, France
| | - Fang Fang
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China.
| |
Collapse
|
14
|
Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Schuster T, Grobler AC, Engelman D, Robinson LJ, Kaldor JM, Steer AC. Community control strategies for scabies: A cluster randomised noninferiority trial. PLoS Med 2021; 18:e1003849. [PMID: 34758017 PMCID: PMC8612541 DOI: 10.1371/journal.pmed.1003849] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 11/24/2021] [Accepted: 10/14/2021] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Scabies is a neglected tropical disease hyperendemic to many low- and middle-income countries. Scabies can be successfully controlled using mass drug administration (MDA) using 2 doses of ivermectin-based treatment. If effective, a strategy of 1-dose ivermectin-based MDA would have substantial advantages for implementing MDA for scabies at large scale. METHODS AND FINDINGS We did a cluster randomised, noninferiority, open-label, 3-group unblinded study comparing the effectiveness of control strategies on community prevalence of scabies at 12 months. All residents from 35 villages on 2 Fijian islands were eligible to participate. Villages were randomised 1:1:1 to 2-dose ivermectin-based MDA (IVM-2), 1-dose ivermectin-based MDA (IVM-1), or screen and treat with topical permethrin 5% for individuals with scabies and their household contacts (SAT). All groups also received diethylcarbamazine and albendazole for lymphatic filariasis control. For IVM-2 and IVM-1, oral ivermectin was dosed at 200 μg/kg and when contraindicated substituted with permethrin. We designated a noninferiority margin of 5%. We enrolled 3,812 participants at baseline (July to November 2017) from the 35 villages with median village size of 108 (range 18 to 298). Age and sex of participants were representative of the population with 51.6% male and median age of 25 years (interquartile range 10 to 47). We enrolled 3,898 at 12 months (July to November 2018). At baseline, scabies prevalence was similar in all groups: IVM-2: 11.7% (95% confidence interval (CI) 8.5 to 16.0); IVM-1: 15.2% (95% CI 9.4 to 23.8); SAT: 13.6% (95% CI 7.9 to 22.4). At 12 months, scabies decreased substantially in all groups: IVM-2: 1.3% (95% CI 0.6 to 2.5); IVM-1: 2.7% (95% CI 1.1 to 6.5); SAT: 1.1% (95% CI 0.6 to 2.0). The risk difference in scabies prevalence at 12 months between the IVM-1 and IVM-2 groups was 1.2% (95% CI -0.2 to 2.7, p = 0.10). Limitations of the study included the method of scabies diagnosis by nonexperts, a lower baseline prevalence than anticipated, and the addition of diethylcarbamazine and albendazole to scabies treatment. CONCLUSIONS All 3 strategies substantially reduced prevalence. One-dose was noninferior to 2-dose ivermectin-based MDA, as was a screen and treat approach, for community control of scabies. Further trials comparing these approaches in varied settings are warranted to inform global scabies control strategies. TRIAL REGISTRATION Clinitrials.gov NCT03177993 and ANZCTR N12617000738325.
Collapse
Affiliation(s)
- Myra Hardy
- Tropical Diseases, Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
| | - Josaia Samuela
- Fiji Ministry of Health and Medical Services, Suva, Fiji
| | - Mike Kama
- Fiji Ministry of Health and Medical Services, Suva, Fiji
| | | | - Lucia Romani
- Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Margot J. Whitfeld
- St Vincent’s Hospital, University of New South Wales, Sydney, New South Wales, Australia
| | - Christopher L. King
- Center for Global Health and Diseases, Case Western Reserve University and Veterans Affairs Medical Center, Cleveland, Ohio, United States of America
| | - Gary J. Weil
- Department of Medicine, Washington University, St. Louis, Missouri, United States of America
| | - Tibor Schuster
- Department of Family Medicine, McGill University, Montreal, Quebec, Canada
| | - Anneke C. Grobler
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
- Clinical Epidemiology and Biostatistics Unit, Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
| | - Daniel Engelman
- Tropical Diseases, Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
| | - Leanne J. Robinson
- Vector-borne Diseases and Tropical Public Health, Burnet Institute, Melbourne, Victoria, Australia
| | - John M. Kaldor
- Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Andrew C. Steer
- Tropical Diseases, Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
- * E-mail:
| |
Collapse
|
15
|
Al Khoury C, Nemer N, Bernigaud C, Fischer K, Guillot J. First evidence of the activity of an entomopathogenic fungus against the eggs of Sarcoptes scabiei. Vet Parasitol 2021; 298:109553. [PMID: 34388422 DOI: 10.1016/j.vetpar.2021.109553] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 07/27/2021] [Accepted: 08/02/2021] [Indexed: 11/29/2022]
Abstract
The entomopathogenic fungus Beauveria bassiana has been successfully used for the control of phytopathogenic arthropods and there are a growing number of studies suggesting that this kind of fungus could also be used for the control of ectoparasites in mammals. This study evaluated for the first time the efficacy of different Beauveria strains against the eggs of Sarcoptes scabiei collected from experimentally infected pigs. Eggs were exposed to fungal conidia and monitored for hatching over 10 days. The strongest effect (28.75 % of hatching inhibition) was obtained with a commercial B. bassiana strain. Furthermore, the detection of fungal genomic within the surface-cleaned eggs demonstrated the ability of B. bassiana to penetrate and proliferate in the egg-shell of S. scabiei. This study provides the first evidence, using molecular techniques, that the development of mycoacaricides may be of interest for the control of S. scabiei infection.
Collapse
Affiliation(s)
- Charbel Al Khoury
- Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Byblos Campus, P.O. Box 36, Byblos, Lebanon; EA 7380 Dynamic, Ecole nationale vétérinaire d'Alfort, UPEC, USC ANSES, 7 Avenue du Général de Gaulle, 94700, Maisons-Alfort, France.
| | - Nabil Nemer
- Department of Agriculture and Food Engineering, Holy Spirit University of Kaslik, P.O.Box 446, Jounieh, Lebanon
| | - Charlotte Bernigaud
- EA 7380 Dynamic, Ecole nationale vétérinaire d'Alfort, UPEC, USC ANSES, 7 Avenue du Général de Gaulle, 94700, Maisons-Alfort, France; Dermatology Department, AP-AH, Henri Mondor Hospital, Université Paris-Est, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France
| | - Katja Fischer
- Scabies Laboratory, QIMR Berghofer Medical Research Institute, Infectious Diseases Program, Brisbane, Australia
| | - Jacques Guillot
- EA 7380 Dynamic, Ecole nationale vétérinaire d'Alfort, UPEC, USC ANSES, 7 Avenue du Général de Gaulle, 94700, Maisons-Alfort, France
| |
Collapse
|
16
|
Wyber R, Noonan K, Halkon C, Enkel S, Cannon J, Haynes E, Mitchell AG, Bessarab DC, Katzenellenbogen JM, Bond-Smith D, Seth R, D'Antoine H, Ralph AP, Bowen AC, Brown A, Carapetis JR. Ending rheumatic heart disease in Australia: the evidence for a new approach. Med J Aust 2020; 213 Suppl 10:S3-S31. [PMID: 33190287 DOI: 10.5694/mja2.50853] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
■The RHD Endgame Strategy: the blueprint to eliminate rheumatic heart disease in Australia by 2031 (the Endgame Strategy) is the blueprint to eliminate rheumatic heart disease (RHD) in Australia by 2031. Aboriginal and Torres Strait Islander people live with one of the highest per capita burdens of RHD in the world. ■The Endgame Strategy synthesises information compiled across the 5-year lifespan of the End Rheumatic Heart Disease Centre of Research Excellence (END RHD CRE). Data and results from priority research projects across several disciplines of research complemented literature reviews, systematic reviews and narrative reviews. Further, the experiences of those working in acute rheumatic fever (ARF) and RHD control and those living with RHD to provide the technical evidence for eliminating RHD in Australia were included. ■The lived experience of RHD is a critical factor in health outcomes. All future strategies to address ARF and RHD must prioritise Aboriginal and Torres Strait Islander people's knowledge, perspectives and experiences and develop co-designed approaches to RHD elimination. The environmental, economic, social and political context of RHD in Australia is inexorably linked to ending the disease. ■Statistical modelling undertaken in 2019 looked at the economic and health impacts of implementing an indicative strategy to eliminate RHD by 2031. Beginning in 2019, the strategy would include: reducing household crowding, improving hygiene infrastructure, strengthening primary health care and improving secondary prophylaxis. It was estimated that the strategy would prevent 663 deaths and save the health care system $188 million. ■The Endgame Strategy provides the evidence for a new approach to RHD elimination. It proposes an implementation framework of five priority action areas. These focus on strategies to prevent new cases of ARF and RHD early in the causal pathway from Streptococcus pyogenes exposure to ARF, and strategies that address the critical systems and structural changes needed to support a comprehensive RHD elimination strategy.
Collapse
Affiliation(s)
- Rosemary Wyber
- George Institute for Global Health, Sydney, NSW.,Telethon Kids Institute, Perth, WA
| | | | | | | | | | | | | | | | | | | | - Rebecca Seth
- Telethon Kids Institute, Perth, WA.,University of Western Australia, Perth, WA
| | | | | | - Asha C Bowen
- Telethon Kids Institute, Perth, WA.,Perth Children's Hospital, Perth, WA
| | - Alex Brown
- South Australian Health and Medical Research Institute, Adelaide, SA.,University of South Australia, Adelaide, SA
| | | | | |
Collapse
|
17
|
Kim M, Kim SK, Hong MJ, Kwak SH, Kim EO, Bae M, Kim MJ, Lee WJ, Kim SH, Jung J, Chang SE. Importance of Follow-Up Microscopic Examination in Hospitalized Patients with Confirmed Scabies. Am J Trop Med Hyg 2020; 103:2539-2541. [PMID: 32996448 DOI: 10.4269/ajtmh.20-0318] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
We investigated the duration of positive microscopic examination in hospitalized patients with confirmed scabies in an acute care hospital. We included hospitalized patients who were diagnosed with scabies between January 2015 and June 2019. From the study period, a total of 31 patients with confirmed scabies were identified. Median age was 75 years. Of a total of 31 patients with confirmed scabies, six were discharged or transferred before getting a negative microscopic test result. Of the remaining 25 patients with negative microscopic test results, the median duration from diagnosis to a negative microscopic test result was 14 days (interquartile range, 9-17). Given that nosocomial outbreaks lead to high workload and considerable resource consumption, adequate treatment, sufficient follow-up examination, and confirmation of cure are warranted before releasing contact isolation.
Collapse
Affiliation(s)
- Miseo Kim
- Office for Infection Control, Asan Medical Center, Seoul, Republic of Korea
| | - Sun-Kyung Kim
- Office for Infection Control, Asan Medical Center, Seoul, Republic of Korea
| | - Min Jee Hong
- Office for Infection Control, Asan Medical Center, Seoul, Republic of Korea
| | - Sun Hee Kwak
- Office for Infection Control, Asan Medical Center, Seoul, Republic of Korea
| | - Eun Ok Kim
- Office for Infection Control, Asan Medical Center, Seoul, Republic of Korea
| | - Moonsuk Bae
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Min Jae Kim
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Woo Jin Lee
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Sung-Han Kim
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.,Office for Infection Control, Asan Medical Center, Seoul, Republic of Korea
| | - Jiwon Jung
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.,Office for Infection Control, Asan Medical Center, Seoul, Republic of Korea
| | - Sung Eun Chang
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
18
|
Fang F, Li M, Jiang Z, Lu X, Guillot J, Si H. Comparing acaricidal and ovicidal activity of five terpenes from essential oils against Psoroptes cuniculi. Parasitol Res 2020; 119:4219-4223. [PMID: 32725319 DOI: 10.1007/s00436-020-06823-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 07/19/2020] [Indexed: 10/23/2022]
Abstract
Essential oils and their components represent an appealing alternative strategy against parasitic mites. The chemical complexity and variability of essential oils limit their use and additional work is required to analyze the efficacy and application rate of essential oils' individual components. In the present study, the activity of five terpenes (terpinen-4-ol, citral, linalool, eugenol, and geraniol) was evaluated against Psoroptes cuniculi motile stages and eggs collected from naturally infected rabbits. Eugenol presented the best acaricidal efficacy with a median lethal concentration (LC50) value of less than 0.1% at 24 h, followed by geraniol (0.33%), linalool (0.38%), citral (0.46%), and terpinen-4-ol (0.66%). Geraniol and eugenol were able to kill all mites within 5 min at 1% concentration. The effective concentration to inhibit 50% (EC50) of egg hatching was 0.65%, 0.66%, 0.85%, 1.47%, and 2.87% for eugenol, geraniol, citral, terpinen-4-ol, and linalool, respectively. In conclusion, eugenol, geraniol, citral, terpinen-4-ol, and linalool should be considered as promising agents for the development of botanical acaricides against Psoroptes cuniculi.
Collapse
Affiliation(s)
- Fang Fang
- College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Meilin Li
- College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Zitao Jiang
- College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Xiaodan Lu
- College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Jacques Guillot
- Research Group Dynamyc, Ecole Nationale Vétérinaire d'Alfort, UPEC, USC ANSES, Maisons-Alfort, France
| | - Hongbin Si
- College of Animal Science and Technology, Guangxi University, Nanning, China.
| |
Collapse
|
19
|
Matthewman J, Manego RZ, Dimessa Mbadinga LB, Šinkovec H, Völker K, Akinosho M, Haedrich C, Tardif d’Hamonville J, Lell B, Adegnika AA, Ramharter M, Mombo-Ngoma G. A randomized controlled trial comparing the effectiveness of individual versus household treatment for Scabies in Lambaréné, Gabon. PLoS Negl Trop Dis 2020; 14:e0008423. [PMID: 32589632 PMCID: PMC7347237 DOI: 10.1371/journal.pntd.0008423] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 07/09/2020] [Accepted: 05/25/2020] [Indexed: 11/18/2022] Open
Abstract
Background It is unclear whether individual treatment of scabies is similarly effective compared to household treatment. This study compared these two treatment strategies with topical benzyl benzoate for treating scabies in Lambaréné, Gabon. Methods Participants presenting with uncomplicated scabies were randomized into either the Individual Treatment group, where only the affected participants received treatment, or the Household Treatment group, where all family members were treated in parallel to the affected participants regardless of signs and symptoms. The primary endpoint was clinical cure after 28 days; the secondary endpoint was the proportion of affected household members per household after 28 days. Results After 28 days, from a total of 79 participants assessed, 67% (n = 53) were clinically cured; 59% (20/34) in the Individual Treatment group and 73% (33/45) in the Household Treatment group. Participants in the Household Treatment group had about twice the odds of being cured (odds ratio 1.9, 95% confidence interval: 0.8–4.9; p = 0.17). For the secondary outcome, an effect of similar size was observed. Conclusions Our findings show that treating close contacts of persons affected by scabies may be beneficial to patients and contacts, however, the benefit was less pronounced than anticipated and further research is needed to definitively answer this question. Scabies is a skin disease caused by parasitic mites that burrow into the skin and cause itchiness and rash. Since these mites can be easily transmitted from person to person the disease is highly contagious. Many guidelines on the treatment of scabies recommend that all family members and close contacts of persons suffering from scabies should be treated alongside the affected person, in order to prevent the disease from spreading. However, there is only little evidence to be found in the medical literature on how well this practice works. We conducted a study in Lambaréné, Gabon and surrounding villages, where many cases of scabies occurred at the time, to answer this question. We found that, on average, those patients whose entire family was treated were more likely to be cured after 4 weeks, and that fewer of their family members were affected. However, the difference to patients whose families weren’t treated was smaller than expected, suggesting that larger studies are needed to definitively answer the question.
Collapse
Affiliation(s)
- Julian Matthewman
- Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
- Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, & I Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- * E-mail: (JM); (GMN)
| | - Rella Zoleko Manego
- Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, & I Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - Hana Šinkovec
- Center for Medical Statistics, Informatics and Intelligent Systems, Institute of Clinical Biometrics, Medical University of Vienna, Vienna, Austria
| | - Katrin Völker
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, & I Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Malik Akinosho
- Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
| | | | | | - Bertrand Lell
- Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
- Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria
| | - Ayola Akim Adegnika
- Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
- Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany
| | - Michael Ramharter
- Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, & I Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Ghyslain Mombo-Ngoma
- Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
- Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, & I Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- * E-mail: (JM); (GMN)
| |
Collapse
|
20
|
[Increase of scabies and therapy resistance among German military personnel : An 8-year follow-up study in the Department of Dermatology of the Armed Forces Hospital Berlin, Germany (2012-2019)]. Hautarzt 2020; 71:447-454. [PMID: 32430543 DOI: 10.1007/s00105-020-04608-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND The diagnosis of scabies has become surprisingly frequent in Germany in recent years and the use of scabicides has risen significantly. OBJECTIVE The aim of our survey was to determine whether this trend can also be detected among military personnel of the German Armed Forces (Bundeswehr). METHODS The study was conducted as a retrospective single-center study over a period of 8 years from 2012 to 2019 in the Department of Dermatology of the Armed Forces Hospital Berlin, Germany. Data were generated from the hospital information system (KIS), which was searched for all scabies-coded diagnoses according to ICD10 code B86 both as outpatients and inpatients. Only first presentations with scabies diagnosis confirmed by dermoscopy or microscopy by a dermatologist were included. Inpatient treatment was required if a patient was not cured after at least three antiscabies treatment cycles in the outpatient setting. RESULTS The data show that there has been a steady increase in the diagnosis of scabies in Bundeswehr personnel. Moreover, our data show that the number of unsuccessfully treated outpatients increased and required in-hospital treatment. CONCLUSION We observed an increase of scabies among German military personnel who represent a typical at-risk group. These results support the observations of an increased incidence of scabies in Germany in general and especially in an at-risk population. With the general increase in scabies cases, there are also increasing numbers of German military personnel who are refractory to treatment, which was largely attributed to inadequate treatment of contact persons and individual treatment errors. Nevertheless, the data also emphasize the low overall prevalence of scabies; therefore, all diagnoses should be confirmed by dermoscopy or microscopy after 14 days whenever possible to rule out the bias of overreporting due to false-positive cases diagnosed only by clinical examination.
Collapse
|
21
|
In Vitro Activity of Beauvericin against All Developmental Stages of Sarcoptes scabiei. Antimicrob Agents Chemother 2020; 64:AAC.02118-19. [PMID: 32122897 DOI: 10.1128/aac.02118-19] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2019] [Accepted: 02/23/2020] [Indexed: 12/22/2022] Open
Abstract
Scabies is a frequent cutaneous infection caused by the mite Sarcoptes scabiei in a large number of mammals, including humans. As the resistance of S. scabiei against several chemical acaricides has been previously documented, the establishment of alternative and effective control molecules is required. In this study, the potential acaricidal activity of beauvericin was assessed against different life stages of S. scabiei var. suis and in comparison with dimpylate and ivermectin, two commercially available molecules used for the treatment of S. scabiei infection in animals and/or humans. The toxicity of beauvericin against cultured human fibroblast skin cells was evaluated using an MTT proliferation assay. In our in vitro model, developmental stages of S. scabiei were placed in petri dishes filled with Columbia agar supplemented with pig serum and different concentrations of the drugs. Cell sensitivity assays demonstrated low toxicity of beauvericin against primary human fibroblast skin cells. At 0.5 and 5 mM, beauvericin showed higher activity against adults and eggs of S. scabiei compared to dimpylate and ivermectin. These results revealed that the use of beauvericin is promising and might be considered for the treatment of S. scabiei infection.
Collapse
|
22
|
Li M, Liu B, Bernigaud C, Fischer K, Guillot J, Fang F. Lemongrass (Cymbopogon citratus) oil: A promising miticidal and ovicidal agent against Sarcoptes scabiei. PLoS Negl Trop Dis 2020; 14:e0008225. [PMID: 32251453 PMCID: PMC7162540 DOI: 10.1371/journal.pntd.0008225] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 04/16/2020] [Accepted: 03/17/2020] [Indexed: 01/30/2023] Open
Abstract
Background Essential oils may represent an alternative strategy for controlling scabies, a neglected tropical disease caused by the infestation of mite from the species Sarcoptes scabiei. Lemongrass (Cymbopogen citratus) oil is reported to possess pharmacological properties including antiparasitc, antioxidant, antimicrobial and anti-inflammatory. The aim of the present study was to assess the potential efficacy of lemongrass oil against the mites and eggs of Sarcoptes scabiei. Methodology/Principal findings Mass spectrometry analysis confirmed that the main component presented in lemongrass oil was citral. Lemongrass oil at concentrations of 10% and 5% killed all Sarcoptes mites within 10 and 25 min, respectively. The median lethal concentration value was 1.37%, 1.08%, 0.91%, 0.64%, and 0.48% at 1, 3, 6, 12, and 24 h, respectively. Lemongrass oil at all concentrations (10%, 5%, 1%, 0.5%, 0.1%) was able to significantly decrease the hatching rate of Sarcoptes eggs. Conclusions/Significance Lemongrass oil should be considered as a promising miticidal and ovicidal agent for scabies control. Scabies is a parasitic infestation which affects about 455 million people annually, with a particularly high prevalence in low income tropical regions. The disease is frequently complicated by bacterial infections. Currently available treatments do not meet the ideal profile which includes miticides, ovicidal, antibacterial and anti-inflammatory/antipruritic properties. Cymbopogon citratus is a plant widely cultivated in tropical and subtropical regions. The essential oil from C. citratus is known as lemongrass oil with reported antimicrobial and anti-inflammatory properties. We conducted experiments to assess the miticidal and ovicidal efficacy of lemongrass oil against Sarcoptes mites collected from naturally infected rabbits in China. The results demonstrated that lemongrass oil can kill the motile stages of Sarcoptes mites effectively and presented a significant ovicidal activity. Considering all these properties, lemongrass oil should be considered a promissing miticide against scabies.
Collapse
Affiliation(s)
- Meilin Li
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
| | - Buming Liu
- Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards, Guangxi Institute of Traditional Medical and Pharmaceutical sciences, Nanning, China
| | - Charlotte Bernigaud
- EA 7380 Dynamyc, Faculté de Médecine de Créteil, UPEC, EnvA, USC Anses, Ecole nationale vétérinaire d’Alfort, Maisons-Alfort, France
- Dermatology Department, AP-HP, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
| | - Katja Fischer
- Cellular and Molecular Biology Department, Infectious Diseases Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Jacques Guillot
- EA 7380 Dynamyc, Faculté de Médecine de Créteil, UPEC, EnvA, USC Anses, Ecole nationale vétérinaire d’Alfort, Maisons-Alfort, France
| | - Fang Fang
- Parasitology Department, College of Animal Science and Technology, Guangxi University, Nanning, China
- * E-mail:
| |
Collapse
|